Jay Bhattacharya, nominee for National Institutes of Health director, and FDA pick Marty Makary clear key Senate committee.

Even the threat of cuts has had a chilling effect. The path that the administration is on will devastate STEM research in ...

Alzheimer’s research requires studies that can last for decades, said Dr. Thomas Grabowski, the center’s director and a professor of radiology and neurology at the UW School of Medicine. Those studies ...

The Trump administration is canceling studies about ways to improve vaccine trust and access. The move comes in the midst of ...

The study relies on 24/7 measurements of patients to investigate whether ultra-processed foods cause people to eat more ...

We are risking an entire generation of medical professionals, researchers, and scientists … and it's a future disaster ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...

1. FDA, NIH nominees clear first hurdle. The HELP Committee voted March 13 to advance both Jay Bhattacharya, MD, PhD, as NIH director in a 12-11 vote and Marty Makary, MD, as FDA commissioner in a ...

Some of terminated grants focused on boosting uptake in minority populations, with the cuts covering a range of vaccines.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...